Uzabase Competitors

Delisted . USA . 
Stock . Uzabase
UBAZFDelisted Stock  USD 11.05  0.00  0.00%   
Uzabase competes with Regeneron Pharmaceuticals, Mink Therapeutics, Anheuser Busch, Tarsus Pharmaceuticals, and Ardelyx; as well as few others. The company classifies itself under Financial Services sector and is part of Capital Markets industry. Analyzing Uzabase competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Uzabase to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Uzabase competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
11.0511.0511.05
Details
Intrinsic
Valuation
LowRealHigh
9.179.1712.16
Details
Naive
Forecast
LowNextHigh
11.2011.2011.20
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
11.0511.0511.05
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Uzabase. Your research has to be compared to or analyzed against Uzabase's peers to derive any actionable benefits. When done correctly, Uzabase's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Uzabase.

Uzabase Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Uzabase and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Uzabase and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Uzabase does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ARDX
+ 0.73
BUD
BUD
+ 0.72
REGN
CMRX
+ 0.69
ABOS
ARDX
+ 0.59
REGN
INKT
+ 0.54
REGN
CMRX
+ 0.34
TARS
  
High negative correlations   
TARS
- 0.95
REGN
TARS
- 0.73
BUD
ARDX
- 0.6
TARS
TARS
- 0.47
INKT
CMRX
- 0.4
BUD
CMRX
- 0.26
REGN

Risk-Adjusted Indicators

There is a big difference between Uzabase Pink Sheet performing well and Uzabase Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Uzabase's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Uzabase Competitive Analysis

The better you understand Uzabase competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Uzabase's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Uzabase's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
UBAZF REGN INKT BUD TARS ARDX ABOS CMRX
 0.00 
 11.05 
Uzabase
 0.24 
 754.87 
Regeneron
 4.35 
 0.72 
Mink
 0.28 
 54.08 
Anheuser
 2.38 
 50.84 
Tarsus
 6.36 
 5.69 
Ardelyx
 2.73 
 2.26 
Acumen
 0.56 
 0.91 
Chimerix
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Relatively risky
Very steady
Very steady
Moderately volatile
Relatively risky
Risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Solid
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very Small
Very High
Below Average
Low
Low
Average
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Under Valued
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Strong Sell
Cautious Hold
Buy
Strong Sell
Sell
Strong Sell
Current Ratio
1.68 X
5.36 X
1.74 X
0.67 X
21.36 X
2.31 X
37.21 X
2.18 X
Net Asset
20.29 B
33.08 B
4.55 M
221.02 B
265.49 M
297.58 M
310.12 M
212.77 M
Profit Margin
0.05 %
0.34 %
N/A
0.11 %
(1.04) %
(0.29) %
N/A
N/A
EBITDA
1.68 B
4.05 B
(22.25 M)
18.97 B
(131.67 M)
(55.35 M)
(51.61 M)
(92.97 M)
Operating Margin
0.02 %
0.33 %
N/A
0.27 %
(0.52) %
0.02 %
N/A
(953.58) %
Current Valuation
379.05 M
75.66 B
26.92 M
176.26 B
1.65 B
1.18 B
(39.7 M)
(54.27 M)
Price To Book
7.49 X
2.82 X
10.05 X
1.35 X
7.99 X
8.01 X
0.61 X
0.60 X
Retained Earnings
N/A
27.26 B
(133.4 M)
42.22 B
(244.66 M)
(846.2 M)
(222.8 M)
(795.52 M)
Current Asset
N/A
2.92 B
N/A
18.29 B
N/A
112.03 M
N/A
228.84 M
Five Year Return
N/A
N/A
N/A
2.56 %
N/A
N/A
N/A
N/A
Beta
1.89
0.14
0.048
1.02
1.0
0.91
0.039
1.13
Number Of Employees
779
14.16 K
31
155 K
244
267
51
72
Shares Outstanding
37.97 M
108.07 M
39.55 M
1.75 B
38.23 M
236.85 M
60.08 M
89.94 M
Cash Flow From Operations
2.7 B
4.59 B
(15.76 M)
13.27 B
(117.49 M)
(89.72 M)
(43.06 M)
(69.09 M)
Annual Yield
N/A
N/A
N/A
0.02 %
N/A
N/A
N/A
N/A
Total Debt
2.69 B
2.7 B
22.61 M
78.17 B
31.73 M
55.98 M
28.49 M
1.3 M
Return On Equity
0.12
0.17
-12.39
0.0839
-0.6
-0.42
-0.33
-0.49
Return On Asset
0.0085
0.0741
-0.97
0.0435
-0.27
-0.12
-0.21
-0.3
Book Value Per Share
202.81 X
272.04 X
(0.52) X
39.82 X
6.22 X
0.67 X
3.62 X
1.51 X
Number Of Shares Shorted
N/A
1.85 M
51.73 K
4.42 M
8.16 M
24.06 M
1.45 M
1.52 M
Current Liabilities
N/A
811.16 M
N/A
28.46 B
N/A
7.72 M
N/A
20.18 M
Total Asset
20.29 B
33.08 B
4.55 M
221.02 B
265.49 M
297.58 M
310.12 M
212.77 M
Debt To Equity
0.42 %
0.13 %
N/A
1.01 %
0.09 %
0.56 %
N/A
0.1 %
Short Ratio
N/A
2.14 X
1.10 X
2.56 X
7.09 X
4.69 X
6.21 X
2.74 X
Target Price
N/A
1078.11
6.67
73.6
65.33
10.67
10.8
7.0
Shares Owned By Institutions
3.83 %
90.85 %
2.25 %
6.01 %
91.30 %
61.46 %
78.48 %
45.90 %
Market Capitalization
430.46 M
82.75 B
28.63 M
108.82 B
1.9 B
1.27 B
132.18 M
81.31 M
Price To Earning
433.00 X
15.51 X
N/A
22.82 X
N/A
(2.11) X
N/A
(3.43) X
Price To Earnings To Growth
N/A
1.12 X
N/A
0.77 X
0.28 X
(0.08) X
(0.23) X
N/A
Price To Sales
0.02 X
5.98 X
N/A
1.83 X
14.65 X
5.03 X
538.78 X
511.39 X
Net Income
589 M
3.95 B
(22.46 M)
5.34 B
(135.89 M)
(66.07 M)
(52.37 M)
(82.09 M)
Earnings Per Share
0.17 X
40.44 X
(0.37) X
3.20 X
(3.75) X
(0.32) X
(1.38) X
(0.94) X
Shares Owned By Insiders
100.00 %
1.56 %
74.64 %
N/A
8.70 %
1.70 %
11.23 %
6.62 %
Revenue
16.06 B
13.12 B
N/A
59.38 B
17.45 M
124.46 M
N/A
324 K
Working Capital
N/A
16.06 B
(7.8 M)
(13.79 B)
219.19 M
195.72 M
233.64 M
170.67 M
Cash And Equivalents
9.24 B
7.02 B
29.85 M
N/A
245.36 M
90.62 M
189.91 M
42.79 M
Cash Per Share
251.74 X
65.75 X
0.88 X
0.61 X
9.20 X
0.48 X
4.69 X
0.49 X
Gross Profit
9.78 B
7.02 B
N/A
31.48 B
(17.76 M)
15.54 M
(32.36 M)
(36.49 M)
Day Typical Price
11.05
755.51
0.72
54.23
50.75
5.58
2.28
0.91
Accumulation Distribution
N/A
9005.69
184.34
14502.89
14272.55
277617.0
0.0756
0.043
Market Facilitation Index
N/A
0.0
0.0
N/A
0.0
N/A
0.18
0.04
Daily Balance Of Power
0.0
0.1457
3.0
0.2885
0.7815
0.8293
0.3333
0.125
Period Momentum Indicator
N/A
1.84
0.03
0.15
1.18
0.34
0.06
0.005
Rate Of Daily Change
1.0
1.0
1.04
1.0
1.02
1.06
1.03
1.01
Day Median Price
11.05
755.84
0.73
54.31
50.71
5.53
2.29
0.91
Price Action Indicator
N/A
(0.04)
0.01
(0.16)
0.73
0.34
N/A
(0)
Relative Strength Index
100.0
15.48
67.07
20.49
66.17
31.5
41.58
N/A
Coefficient Of Variation
787.4
(247.22)
(1,789)
(684.15)
368.25
(2,903)
(1,459)
(4,203)
Mean Deviation
0.3332
1.17
1.82
0.8919
2.65
2.91
3.56
2.42
Jensen Alpha
0.2069
(0.80)
(0.20)
(0.23)
0.8427
(0.43)
(0.68)
(0.25)
Total Risk Alpha
(0.05)
(0.97)
(0.51)
(0.40)
0.3896
(0.85)
(1.08)
(0.60)
Sortino Ratio
N/A
N/A
N/A
N/A
0.3604
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
5.19
N/A
N/A
N/A
Standard Deviation
1.33
1.7
2.36
1.27
3.5
4.38
4.75
3.24
Kurtosis
62.0
8.66
0.2842
5.03
1.63
7.47
1.57
0.0399
Potential Upside
N/A
1.17
4.05
1.36
6.32
4.78
7.52
5.43
Treynor Ratio
(0.40)
(0.84)
(0.29)
(0.66)
1.15
(0.07)
(0.12)
(0.07)
Maximum Drawdown
10.5
11.18
12.3
9.38
16.85
33.99
28.07
14.98
Variance
1.78
2.89
5.58
1.62
12.28
19.16
22.54
10.51
Market Risk Adjusted Performance
(0.39)
(0.83)
(0.28)
(0.65)
1.16
(0.06)
(0.11)
(0.06)
Risk Adjusted Performance
0.1014
(0.30)
(0.04)
(0.11)
0.2154
(0.02)
(0.04)
(0.01)
Skewness
7.87
(2.18)
(0.01)
(0.86)
1.05
(1.31)
(0.32)
0.07
Semi Deviation
N/A
N/A
N/A
N/A
1.81
N/A
N/A
N/A
Information Ratio
0.0292
(0.48)
(0.11)
(0.25)
0.2343
(0.06)
(0.1)
(0.06)
Value At Risk
N/A
(3.28)
(3.85)
(2.02)
(3.85)
(6.13)
(6.78)
(5.56)
Expected Short fall
N/A
N/A
N/A
N/A
(3.45)
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
2.28
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
3.28
N/A
N/A
N/A

Uzabase Competition Performance Charts

Five steps to successful analysis of Uzabase Competition

Uzabase's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Uzabase in relation to its competition. Uzabase's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Uzabase in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Uzabase's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Uzabase, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Uzabase position

In addition to having Uzabase in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Funds Thematic Idea Now

Healthcare Funds
Healthcare Funds Theme
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Uzabase Pink Sheet

If you are still planning to invest in Uzabase check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Uzabase's history and understand the potential risks before investing.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY